stockrow
Friday 6 November 2026
Export IRON’s income statement to Excel — free account
Disc Medicine, Inc.
IRON Healthcare Biotechnology
- EPS
- +2.53%
- Free cash flow
- +7.83%
- Total debt
- +106.5%
Quarter to June 2026, against a year earlier
78.51
0.04
+0.05%
Follow IRON
Alert me
Disc Medicine, Inc. (IRON) EPS (diluted)
Disc Medicine, Inc.'s EPS (diluted) for fiscal 2025 was −$6.01, compared with −$3.96 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$6.58. Over the past ten years it has ranged from −$45.05 (fiscal 2022) to −$3.42 (fiscal 2023); the current reading is higher than 67% of that period. Disc Medicine, Inc. ranks 470th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$6.01 | — |
| FY2024 | −$3.96 | — |
| FY2023 | −$3.42 | — |
| FY2022 | −$45.05 | — |
| FY2021 | −$40.97 | — |
| FY2020 | −$27.02 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$1.54 | — |
| Mar 2026 | −$1.65 | — |
| Dec 2025 | −$1.62 | — |
| Sep 2025 | −$1.77 | — |
| 22 more quarters | Free account |
Against its own ten years
Low −$45.05
High −$3.42
Ten-year median
−$16.51
Current reading's percentile
67
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $2.11 |
| IOVA Iovance Biotherapeutics, Inc. compare | −$0.53 |
| TNGX Tango Therapeutics, Inc. compare | −$0.85 |
| RLAY Relay Therapeutics, Inc. compare | −$1.57 |
| DYN Dyne Therapeutics, Inc. compare | −$3.33 |
| XENE Xenon Pharmaceuticals Inc. compare | −$4.74 |
| VKTX Viking Therapeutics, Inc. compare | −$5.40 |
| IRON Disc Medicine, Inc. | −$6.58 |
| PBLS Parabilis Medicines, Inc. compare | −$83.02 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item